JO3117B1 - استعمال 3- كربوكسي- ن-إيثيل- ن، ن- ثاني ميثيل بروبان-1– أمينيوم أو ملح منه مقبول صيدلانياً في معالجة تصلب الشرايين - Google Patents
استعمال 3- كربوكسي- ن-إيثيل- ن، ن- ثاني ميثيل بروبان-1– أمينيوم أو ملح منه مقبول صيدلانياً في معالجة تصلب الشرايينInfo
- Publication number
- JO3117B1 JO3117B1 JOP/2013/0362A JOP20130362A JO3117B1 JO 3117 B1 JO3117 B1 JO 3117B1 JO P20130362 A JOP20130362 A JO P20130362A JO 3117 B1 JO3117 B1 JO 3117B1
- Authority
- JO
- Jordan
- Prior art keywords
- dimethylpropan
- carboxy
- ethyl
- aminium
- pharmaceutically acceptable
- Prior art date
Links
- ISMYCKWHOZKHNJ-UHFFFAOYSA-O 3-carboxypropyl-ethyl-dimethylazanium Chemical compound CC[N+](C)(C)CCCC(O)=O ISMYCKWHOZKHNJ-UHFFFAOYSA-O 0.000 title abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- PPDPFXLNXLDRNM-WLHGVMLRSA-N (e)-but-2-enedioate;3-carboxypropyl-ethyl-dimethylazanium;hydron Chemical compound OC(=O)\C=C\C([O-])=O.CC[N+](C)(C)CCCC(O)=O PPDPFXLNXLDRNM-WLHGVMLRSA-N 0.000 abstract 1
- DQSCWIHGBKJVRY-UHFFFAOYSA-N 3-carboxypropyl-ethyl-dimethylazanium;dihydrogen phosphate Chemical compound OP(O)([O-])=O.CC[N+](C)(C)CCCC(O)=O DQSCWIHGBKJVRY-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12198627 | 2012-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3117B1 true JO3117B1 (ar) | 2017-09-20 |
Family
ID=47458734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2013/0362A JO3117B1 (ar) | 2012-12-20 | 2013-12-11 | استعمال 3- كربوكسي- ن-إيثيل- ن، ن- ثاني ميثيل بروبان-1– أمينيوم أو ملح منه مقبول صيدلانياً في معالجة تصلب الشرايين |
Country Status (11)
| Country | Link |
|---|---|
| CN (1) | CN104869988B (fr) |
| AR (1) | AR094084A1 (fr) |
| BR (1) | BR112015014161B1 (fr) |
| CA (1) | CA2895574C (fr) |
| CU (1) | CU20150067A7 (fr) |
| JO (1) | JO3117B1 (fr) |
| MX (1) | MX362762B (fr) |
| PE (1) | PE20151587A1 (fr) |
| TN (1) | TN2015000236A1 (fr) |
| WO (1) | WO2014096133A1 (fr) |
| ZA (1) | ZA201505093B (fr) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010149654A1 (fr) * | 2009-06-25 | 2010-12-29 | Grindeks, A Joint Stock Company | Composition pharmaceutique de gamma-butyrobétaïne ou sel pharmaceutiquement acceptable et de meldonium ou sel pharmaceutiquement acceptable |
| EA021588B1 (ru) * | 2009-06-25 | 2015-07-30 | Тетра Сиа | Бетаиновые соли ацетилсалициловой кислоты |
| LV14345B (lv) * | 2009-10-22 | 2011-07-20 | Grindeks, A/S | 4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai |
| CA2832693C (fr) * | 2011-04-27 | 2018-10-02 | Grindeks, A Joint Stock Company | Utilisation de sels de 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium pour traiter une maladie cardiovasculaire |
-
2013
- 2013-12-11 JO JOP/2013/0362A patent/JO3117B1/ar active
- 2013-12-18 AR ARP130104820A patent/AR094084A1/es unknown
- 2013-12-19 BR BR112015014161-7A patent/BR112015014161B1/pt active IP Right Grant
- 2013-12-19 WO PCT/EP2013/077291 patent/WO2014096133A1/fr active Application Filing
- 2013-12-19 MX MX2015008138A patent/MX362762B/es active IP Right Grant
- 2013-12-19 CA CA2895574A patent/CA2895574C/fr active Active
- 2013-12-19 PE PE2015000876A patent/PE20151587A1/es not_active Application Discontinuation
- 2013-12-19 CN CN201380066810.0A patent/CN104869988B/zh active Active
-
2015
- 2015-06-01 TN TNP2015000236A patent/TN2015000236A1/fr unknown
- 2015-06-19 CU CUP2015000067A patent/CU20150067A7/es unknown
- 2015-07-15 ZA ZA2015/05093A patent/ZA201505093B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015014161B1 (pt) | 2021-02-17 |
| CA2895574A1 (fr) | 2014-06-26 |
| CN104869988A (zh) | 2015-08-26 |
| CA2895574C (fr) | 2019-11-26 |
| WO2014096133A1 (fr) | 2014-06-26 |
| TN2015000236A1 (en) | 2016-10-03 |
| PE20151587A1 (es) | 2015-12-05 |
| MX362762B (es) | 2019-02-06 |
| ZA201505093B (en) | 2016-04-28 |
| AR094084A1 (es) | 2015-07-08 |
| CN104869988B (zh) | 2017-07-28 |
| MX2015008138A (es) | 2016-04-25 |
| CU20150067A7 (es) | 2016-01-29 |
| BR112015014161A2 (pt) | 2017-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3343B1 (ar) | أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها | |
| SG195110A1 (en) | Pirfenidone and anti-fibrotic therapy in selected patients | |
| SG10201901010PA (en) | Combination therapy for treating a paramyxovirus | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| IN2015DN00895A (fr) | ||
| IN2015DN01156A (fr) | ||
| PH12015502042B1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
| MX356525B (es) | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. | |
| TN2013000508A1 (en) | Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer | |
| MX2013008737A (es) | Formas de dosificacion oral para tasocitinib que comprende liberacion modificada. | |
| MY166936A (en) | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder | |
| EP4357083A3 (fr) | Dispositif robotique à site unique et systèmes et procédés associés | |
| TW201144301A (en) | Processes for preparing linezolid | |
| PT2848097T (pt) | Dispositivo para o tratamento de plasma de superfícies humanas, animais ou de plantas, em particular da pele ou de áreas de membrana mucosa | |
| IN2014DN10670A (fr) | ||
| MX2021005172A (es) | Compuestos de union a nhe3 (intercambiador de sodio-hidrogeno 3) y metodos para inhibir el transporte de fosfato. | |
| WO2013098416A3 (fr) | Composes anti-douleur | |
| TN2012000610A1 (en) | Heterocyclic compounds, their preparation and their therapeutic application | |
| MX359181B (es) | Hidrolizado de colágeno y uso del mismo. | |
| GEP20196984B (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| EP4385563A3 (fr) | Formes posologiques et utilisations thérapeutiques de la l-4-chlorokynurénine | |
| MX2015013755A (es) | Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis. | |
| MX2015007945A (es) | Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas. | |
| AU2012307449A8 (en) | Sulfonic acid salts of heterocyclylamide-substituted imidazoles | |
| MX362111B (es) | Un metodo para mejorar la funcion hepatica. |